<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Clinical presentation and initial evaluation of non-Hodgkin lymphoma</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Clinical presentation and initial evaluation of non-Hodgkin lymphoma</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Clinical presentation and initial evaluation of non-Hodgkin lymphoma</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Arnold S Freedman, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jonathan W Friedberg, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jon C Aster, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Andrew Lister, MD, FRCP, FRCPath, FRCR</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alan G Rosmarin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 06, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Non-Hodgkin lymphomas (NHL) comprise a diverse group of hematologic malignancies that are variously derived from B cell progenitors, T cell progenitors, mature B cells, mature T cells, or (rarely) natural killer cells. NHL is seen in patients of all ages, races, and socioeconomic status. Diagnosis and classification of NHL requires an adequate biopsy specimen and expert pathologic review because the clinical manifestations, prognosis, and management of lymphomas vary widely according to the type of lymphoma.</p><p>This topic will review the clinical presentation and initial evaluation of a patient with suspected NHL.</p><p>Classification of NHL and the general pretreatment evaluation, staging, and response assessment in lymphomas are discussed separately. (See  <a class="medical medical_review" href="/d/html/4716.html" rel="external">"Classification of hematopoietic neoplasms"</a> and  <a class="medical medical_review" href="/d/html/4696.html" rel="external">"Pretreatment evaluation and staging of non-Hodgkin lymphomas"</a>.)</p><p>Treatment and prognosis of specific subtypes of NHL are discussed in those particular topics.</p><p class="headingAnchor" id="H2"><span class="h1">CLINICAL PRESENTATION</span></p><p class="headingAnchor" id="H3"><span class="h2">General</span><span class="headingEndMark"> — </span>The clinical presentation of NHL varies with the histologic subtype and sites of involvement. Some subtypes of NHL manifest variable lymphadenopathy for years, while others are highly aggressive and can cause death within weeks, if untreated. Even within a specific NHL subtype, the clinical presentation varies widely between individual patients. (See  <a class="medical medical_review" href="/d/html/4716.html" rel="external">"Classification of hematopoietic neoplasms", section on 'Lymphoid neoplasms'</a>.)</p><p>Following are examples of typical presentations of NHL:</p><p class="bulletIndent1"><span class="glyph">●</span>Aggressive or highly aggressive lymphomas commonly present subacutely or acutely with a rapidly growing mass; constitutional symptoms of fever, night sweats, or weight loss; and/or tumor lysis syndrome. Examples of aggressive or highly aggressive NHL include diffuse large B cell lymphoma, Burkitt lymphoma, precursor B and T lymphoblastic leukemia/lymphoma, adult T cell leukemia-lymphoma, and certain other peripheral T cell lymphomas.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Indolent lymphomas are often insidious, presenting with slowly growing or waxing and waning lymphadenopathy over months or years, hepatomegaly, splenomegaly, and/or cytopenias. Examples of indolent NHL include follicular lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, and splenic marginal zone lymphoma.</p><p></p><p>A minority of patients initially present with extranodal lymphoma (primary extranodal NHL), but many more patients develop extranodal disease in the course of their disease (secondary extranodal NHL). Examples of extranodal manifestations of NHL include:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with primary gastrointestinal tract lymphoma may present with anorexia, early satiety, weight loss, vomiting, abdominal fullness, or with visceral obstruction, perforation, or hemorrhage  (<a class="graphic graphic_table graphicRef68593" href="/d/graphic/68593.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/d/html/4743.html" rel="external">"Clinical presentation and diagnosis of primary gastrointestinal lymphomas"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with primary central nervous system lymphoma may present with headache, lethargy, focal neurologic symptoms, seizures, paralysis, spinal cord compression, or lymphomatous meningitis. (See  <a class="medical medical_review" href="/d/html/3718.html" rel="external">"Approach to the patient with HIV and central nervous system lesions"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with cutaneous lymphoma may present with rash that can progress slowly or wax and wane, or with cutaneous plaques, tumors, or ulcers. (See  <a class="medical medical_review" href="/d/html/109157.html" rel="external">"Classification of primary cutaneous lymphomas"</a>.)</p><p></p><p>Some patients present with atypical findings, such as pruritus, exaggerated (hypersensitivity) reactions to insect stings or bites, generalized fatigue, malaise, fever of unknown origin, ascites, or effusions that may accompany nodal or extranodal NHL or, rarely, may be the sole manifestation of a lymphoma.</p><p class="headingAnchor" id="H4"><span class="h2">Oncologic emergencies</span><span class="headingEndMark"> — </span>Life-threatening oncologic emergencies and complications may be recognized at the time of presentation of NHL or may develop during the course of the disease or its treatment. Especially for highly aggressive subtypes, such as Burkitt lymphoma, prompt recognition and management are critical, as these complications may be life-threatening or delay treatment of the underlying NHL.</p><p>Examples of oncologic complications of NHL and associated clinical manifestations include:</p><p class="bulletIndent1"><span class="glyph">●</span>Spinal cord compression (eg, back pain, weakness, altered sensation, paresthesias, incontinence). (See  <a class="medical medical_review" href="/d/html/2819.html" rel="external">"Clinical features and diagnosis of neoplastic epidural spinal cord compression"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lymphomatous meningitis and/or central nervous system mass lesions (eg, headache, visual changes, altered sensorium, lethargy, seizures, cranial neuropathies). (See  <a class="medical medical_review" href="/d/html/4521.html" rel="external">"Involvement of the central nervous system (CNS) with acute myeloid leukemia (AML)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Airway obstruction (eg, dyspnea, cough, hemoptysis, wheeze, stridor, tachypnea). (See  <a class="medical medical_review" href="/d/html/4384.html" rel="external">"Clinical presentation, diagnostic evaluation, and management of malignant central airway obstruction in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pericardial tamponade (eg, chest pain, dyspnea, hypotension, peripheral edema, fatigue). (See  <a class="medical medical_review" href="/d/html/4954.html" rel="external">"Pericardial disease associated with cancer: Clinical presentation and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Superior vena cava obstruction (eg, swelling of the face or neck, chest pain, dyspnea, stridor, cough). (See  <a class="medical medical_review" href="/d/html/2832.html" rel="external">"Malignancy-related superior vena cava syndrome"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Gastrointestinal obstruction or liver failure (eg, vomiting, hematemesis, abdominal pain, obstipation, jaundice). (See  <a class="medical medical_review" href="/d/html/4743.html" rel="external">"Clinical presentation and diagnosis of primary gastrointestinal lymphomas"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hydronephrosis or renal failure (eg, flank or groin pain, change in urine output, hematuria, hypertension). (See  <a class="medical medical_review" href="/d/html/7174.html" rel="external">"Clinical manifestations and diagnosis of urinary tract obstruction (UTO) and hydronephrosis"</a> and  <a class="medical medical_review" href="/d/html/7379.html" rel="external">"Uric acid kidney diseases"</a> and  <a class="medical medical_review" href="/d/html/7173.html" rel="external">"Overview of kidney disease in patients with cancer"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Tumor lysis syndrome (eg, nausea, vomiting, anorexia, lethargy, hematuria, heart failure, cardiac dysrhythmias, seizures, muscle cramps, tetany). (See  <a class="medical medical_review" href="/d/html/1154.html" rel="external">"Tumor lysis syndrome: Pathogenesis, clinical manifestations, definition, etiology and risk factors"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hypercalcemia (eg, polyuria, polydipsia, dehydration, anorexia, nausea, muscle weakness, altered sensorium, constipation, fatigue, depression). (See  <a class="medical medical_review" href="/d/html/850.html" rel="external">"Treatment of hypercalcemia"</a> and  <a class="medical medical_review" href="/d/html/832.html" rel="external">"Clinical manifestations of hypercalcemia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Leukostasis or hyperleukocytosis (eg, visual changes, headache, dizziness, tinnitus, gait instability, confusion, somnolence, coma, dyspnea, hypoxia). (See  <a class="medical medical_review" href="/d/html/4522.html" rel="external">"Hyperleukocytosis and leukostasis in hematologic malignancies"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hyperviscosity syndrome (eg, blurring, diplopia, loss of vision, headache, vertigo, nystagmus, tinnitus, sudden deafness, ataxia, confusion, altered consciousness, stroke). (See  <a class="medical medical_review" href="/d/html/6657.html" rel="external">"Epidemiology, pathogenesis, clinical manifestations, and diagnosis of Waldenström macroglobulinemia", section on 'Hyperviscosity syndrome'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Venous thromboembolic disease (eg, deep vein thrombosis, thromboembolism). (See  <a class="medical medical_review" href="/d/html/1361.html" rel="external">"Overview of the causes of venous thrombosis", section on 'Malignancy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Autoimmune hemolytic anemia (eg, dyspnea, fatigue, palpitations, jaundice, dark urine, splenomegaly). (See  <a class="medical medical_review" href="/d/html/7078.html" rel="external">"Warm autoimmune hemolytic anemia (AIHA) in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Immune thrombocytopenia (eg, excessive bruising or bleeding). (See  <a class="medical medical_review" href="/d/html/4513.html" rel="external">"Clinical features and diagnosis of chronic lymphocytic leukemia/small lymphocytic lymphoma", section on 'Cytopenias'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cold agglutinin disease (eg, acrocyanosis, Raynaud phenomenon). (See  <a class="medical medical_review" href="/d/html/7084.html" rel="external">"Cold agglutinin disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Angioedema (eg, angioedema, with or without urticaria or pruritus). (See  <a class="medical medical_review" href="/d/html/8112.html" rel="external">"Acquired C1 inhibitor deficiency: Clinical manifestations, epidemiology, pathogenesis, and diagnosis"</a>.)</p><p></p><p class="headingAnchor" id="H5"><span class="h2">Abnormal laboratory results</span><span class="headingEndMark"> — </span>Some patients with NHL present with abnormal laboratory results, such as:</p><p class="bulletIndent1"><span class="glyph">●</span>Hematologic – Anemia, thrombocytopenia, leukopenia, and/or lymphocytosis can have multiple causes, including bone marrow infiltration, hypersplenism from splenic involvement, or immune destruction. (See  <a class="medical medical_review" href="/d/html/7140.html" rel="external">"Causes of anemia in patients with cancer"</a> and  <a class="medical medical_review" href="/d/html/7149.html" rel="external">"Anemia of chronic disease/anemia of inflammation"</a> and  <a class="medical medical_review" href="/d/html/7078.html" rel="external">"Warm autoimmune hemolytic anemia (AIHA) in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hypercalcemia – Hypercalcemia is uncommon at presentation but can occur with human T-lymphotropic virus type 1 (HTLV-1)-associated adult T cell leukemia-lymphoma and occasionally with transformed follicular lymphoma or diffuse large B cell lymphoma. Symptoms include dehydration, lethargy, weakness, nausea, vomiting, and constipation. (See  <a class="medical medical_review" href="/d/html/842.html" rel="external">"Hypercalcemia of malignancy: Mechanisms"</a> and  <a class="medical medical_review" href="/d/html/4697.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of adult T cell leukemia-lymphoma", section on 'Hypercalcemia and lytic bone lesions'</a> and  <a class="medical medical_review" href="/d/html/4755.html" rel="external">"Treatment of relapsed or refractory follicular lymphoma", section on 'Rule out histologic transformation'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hyperuricemia – Hyperuricemia causing symptoms of gout or nephrolithiasis is unusual at presentation but may be present with tumor lysis syndrome in patients with Burkitt lymphoma and other aggressive or very aggressive NHL. (See  <a class="medical medical_review" href="/d/html/1669.html" rel="external">"Asymptomatic hyperuricemia"</a> and  <a class="medical medical_review" href="/d/html/7379.html" rel="external">"Uric acid kidney diseases"</a> and  <a class="medical medical_review" href="/d/html/1154.html" rel="external">"Tumor lysis syndrome: Pathogenesis, clinical manifestations, definition, etiology and risk factors"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Elevated serum lactate dehydrogenase (LDH) – Elevated LDH may be due to high tumor burden, extensive infiltration of the liver, concurrent hemolytic anemia from immune-mediated red blood cell destruction, or rapidly growing forms of NHL, such as Burkitt lymphoma, lymphoblastic lymphoma, diffuse large B cell lymphoma, or transformed follicular lymphoma.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Abnormal serum protein electrophoresis (SPEP) – A monoclonal immunoglobulin (M-spike) may be detected by SPEP. Relatively large M-spikes (&gt;0.5 g/dL) are most commonly associated with lymphoplasmacytic lymphoma, but other B cell NHLs, particularly small lymphocytic lymphoma/chronic lymphocytic leukemia and extranodal marginal zone lymphoma, may be associated with small M-spikes. (See  <a class="medical medical_review" href="/d/html/4768.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of lymphoplasmacytic lymphoma"</a>.)</p><p></p><p class="headingAnchor" id="H6"><span class="h2">Paraneoplastic syndromes</span><span class="headingEndMark"> — </span>NHL may occasionally be associated with a wide variety of localized or systemic paraneoplastic syndromes. Examples of paraneoplastic syndromes include:</p><p class="bulletIndent1"><span class="glyph">●</span>Neurologic findings, such as encephalopathy, gait instability, visual changes, and motor or sensory dysfunction, in the absence of metabolic and nutritional deficits, infections, or coagulopathy. (See  <a class="medical medical_review" href="/d/html/5188.html" rel="external">"Overview of paraneoplastic syndromes of the nervous system"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sweet syndrome, pruritic or inflammatory seborrheic keratoses, ichthyosis, exfoliative erythroderma, or other cutaneous findings in the absence of direct tumor involvement. (See  <a class="medical medical_review" href="/d/html/7606.html" rel="external">"Cutaneous manifestations of internal malignancy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Polyarthritis, eosinophilic fasciitis, and other rheumatologic manifestations. (See  <a class="medical medical_review" href="/d/html/5615.html" rel="external">"Malignancy and rheumatic disorders", section on 'Paraneoplastic rheumatic manifestations'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Membranous nephropathy, minimal change disease, proteinuria, and other forms of renal dysfunction. (See  <a class="medical medical_review" href="/d/html/7173.html" rel="external">"Overview of kidney disease in patients with cancer"</a>.)</p><p></p><p class="headingAnchor" id="H8"><span class="h1">HISTORY</span><span class="headingEndMark"> — </span>The following aspects of the history are particularly important to evaluate:</p><p class="headingAnchor" id="H3196175287"><span class="h2">Lymphadenopathy</span><span class="headingEndMark"> — </span>Peripheral lymphadenopathy, which is generally firm and painless, is present in more than two-thirds of patients with NHL at presentation. The sites and extent of involvement, rate and pattern of growth, and duration of lymphadenopathy should be documented.</p><p>Lymphadenopathy is commonly associated with infections and other causes. The initial evaluation should attempt to exclude infectious and other etiologies, as discussed separately. (See  <a class="medical medical_review" href="/d/html/8386.html" rel="external">"Evaluation of peripheral lymphadenopathy in adults"</a>.)</p><p class="headingAnchor" id="H3282434100"><span class="h2">Systemic "B" symptoms</span><span class="headingEndMark"> — </span>Unexplained fever, weight loss, or night sweats are referred to as constitutional or "B" symptoms. The duration and pattern of fevers and sweats and extent of weight loss should be documented. The formal definitions of B symptoms follow:</p><p class="bulletIndent1"><span class="glyph">●</span>Fever – Temperature &gt;38°C (&gt;100.4°F)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Weight loss – Unexplained loss of &gt;10 percent of body weight over the past six months</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sweats – The presence of drenching night sweats</p><p></p><p>The presence of constitutional symptoms varies with the subtype of NHL  (<a class="graphic graphic_table graphicRef64113" href="/d/graphic/64113.html" rel="external">table 2</a>) [<a href="#rid1">1</a>]. B symptoms are more common in patients with aggressive and highly aggressive subtypes of NHL, especially in those with hepatic and extranodal involvement. In contrast, only a small percentage of patients with indolent lymphomas have B symptoms; when present, they are usually associated with advanced stage disease and/or with bulky tumor masses.</p><p class="headingAnchor" id="H9"><span class="h2">Past medical history</span><span class="headingEndMark"> — </span>Various diseases, infectious agents, drugs, and toxins have been associated with the development of NHL  (<a class="graphic graphic_table graphicRef77563" href="/d/graphic/77563.html" rel="external">table 3</a>) [<a href="#rid2">2-14</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Personal or family history of lymphoma or other hematologic malignancy, prior radiation or chemotherapy treatment, immunosuppressive agents, organ transplantation, and other underlying diseases should be obtained [<a href="#rid15">15-22</a>]. (See  <a class="medical medical_review" href="/d/html/7335.html" rel="external">"Treatment and prevention of post-transplant lymphoproliferative disorders"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Infections should be evaluated, including HIV, human T-lymphotropic virus type I (HTLV-I), Epstein-Barr virus (EBV), hepatitis B virus (HBV), hepatitis C virus (HCV), <em>Borrelia burgdorferi</em> (<em>B. afzelii</em> species), and <em>Chlamydia psittaci</em> [<a href="#rid23">23-25</a>]. (See  <a class="medical medical_review" href="/d/html/4711.html" rel="external">"Overview of the pathobiology of the non-Hodgkin lymphomas"</a> and  <a class="medical medical_review" href="/d/html/3676.html" rel="external">"Extrahepatic manifestations of hepatitis C virus infection", section on 'Lymphoma'</a> and  <a class="medical medical_review" href="/d/html/7913.html" rel="external">"Clinical manifestations of Lyme disease in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Exposure to agricultural pesticides and dioxin (eg, Agent Orange) may be associated with an increased risk of development of NHL [<a href="#rid2">2</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Rarely, chronic scarring or local inflammation caused by medical or cosmetic interventions contributes to development of lymphoma. Examples include the development of CD30+ anaplastic large cell lymphoma in scar tissue surrounding textured breast implants, and development of EBV-positive large B cell lymphomas in patients with chronic pyothorax secondary to "artificial" pneumothorax, used as a treatment for lung tuberculosis [<a href="#rid26">26,27</a>]. (See  <a class="medical medical_review" href="/d/html/107116.html" rel="external">"Breast implant-associated anaplastic large cell lymphoma"</a>.)</p><p></p><p class="headingAnchor" id="H1177998170"><span class="h2">Associated disorders</span><span class="headingEndMark"> — </span>Disorders that may be associated with NHL include:</p><p class="bulletIndent1"><span class="glyph">●</span>Autoimmune diseases (eg, lupus erythematosus, rheumatoid arthritis, Sjögren's disease, Hashimoto's thyroiditis) [<a href="#rid28">28-31</a>]. (See  <a class="medical medical_review" href="/d/html/5615.html" rel="external">"Malignancy and rheumatic disorders"</a> and  <a class="medical medical_review" href="/d/html/5593.html" rel="external">"Clinical manifestations of Sjögren’s disease: Extraglandular disease", section on 'Hematologic manifestations'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Immunodeficiency disorders, including immunosuppression due to treatment with immunomodulatory drugs. (See  <a class="medical medical_review" href="/d/html/95906.html" rel="external">"Malignancy in inborn errors of immunity"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mixed cryoglobulinemia. (See  <a class="medical medical_review" href="/d/html/1825.html" rel="external">"Overview of cryoglobulins and cryoglobulinemia", section on 'Lymphoproliferative disorders'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Multicentric Castleman disease. (See  <a class="medical medical_review" href="/d/html/4707.html" rel="external">"HHV-8/KSHV-associated multicentric Castleman disease", section on 'Complications'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Inflammatory gastrointestinal diseases (eg, gastrointestinal nodular lymphoid hyperplasia, <em>Helicobacter pylori</em>-associated chronic gastritis, and celiac disease). (See  <a class="medical medical_review" href="/d/html/4743.html" rel="external">"Clinical presentation and diagnosis of primary gastrointestinal lymphomas", section on 'Predisposing conditions'</a> and  <a class="medical medical_review" href="/d/html/4777.html" rel="external">"Management of celiac disease in adults", section on 'Ulcerative jejunitis and intestinal lymphoma'</a>.)</p><p></p><p class="headingAnchor" id="H12"><span class="h2">Fever of unknown origin</span><span class="headingEndMark"> — </span>Fever of unknown origin (FUO) refers to a prolonged febrile illness without an established etiology, despite intensive evaluation and diagnostic testing. Historically, the most common causes of FUO were infection, connective tissue diseases, and malignancy, but the frequency of FUO attributable to malignancy has declined  (<a class="graphic graphic_figure graphicRef73878" href="/d/graphic/73878.html" rel="external">figure 1</a>), likely due to improved imaging techniques. (See  <a class="medical medical_review" href="/d/html/2737.html" rel="external">"Fever of unknown origin in adults: Etiologies"</a> and  <a class="medical medical_review" href="/d/html/2736.html" rel="external">"Fever of unknown origin in adults: Evaluation and management"</a>.)</p><p>Aggressive or highly aggressive subtypes of NHL are a common cause of FUO due to malignancy. In the absence of an obvious site to biopsy (eg, an enlarged peripheral lymph node), bone marrow aspiration/biopsy may provide critical diagnostic information, as may the use of computed tomography (CT) or positron emission tomography (PET) scanning to detect sites of disease suitable for biopsy.</p><p>Intravascular large B cell lymphoma is extremely rare but may present with fever, rash, or prominent and rapidly progressive neurologic signs. Unlike other advanced stage lymphomas, intravascular large B cell lymphoma does not cause cytopenias (even with involvement of marrow sinusoids) or lymph node enlargement, and tumor cells do not appear in the peripheral blood. Biopsy of skin, or sometimes brain, liver, bone marrow, or lung, is required to make a diagnosis and reveals small vessels containing lymphoma cells. (See  <a class="medical medical_review" href="/d/html/2736.html" rel="external">"Fever of unknown origin in adults: Evaluation and management"</a> and  <a class="medical medical_review" href="/d/html/4738.html" rel="external">"Intravascular large B cell lymphoma"</a>.)</p><p class="headingAnchor" id="H13"><span class="h1">PHYSICAL EXAMINATION</span></p><p class="headingAnchor" id="H14"><span class="h2">Lymphoid survey</span><span class="headingEndMark"> — </span>The physical examination should evaluate all potentially involved lymphoid sites  (<a class="graphic graphic_figure graphicRef63663" href="/d/graphic/63663.html" rel="external">figure 2</a>), including:</p><p class="bulletIndent1"><span class="glyph">●</span>Waldeyer's ring (tonsils, base of the tongue, nasopharynx)</p><p class="bulletIndent1"><span class="glyph">●</span>Clinically accessible lymph node sites (eg, cervical, supraclavicular, axillary, inguinal, femoral, epitrochlear, popliteal)</p><p class="bulletIndent1"><span class="glyph">●</span>Liver and spleen</p><p class="bulletIndent1"><span class="glyph">●</span>Abdominal nodal sites (mesenteric, retroperitoneal)</p><p class="bulletIndent1"><span class="glyph">●</span>Less commonly involved nodal sites (eg, occipital, preauricular, epitrochlear, popliteal)</p><p></p><p>There are numerous causes of lymphadenopathy, besides NHL. Clinical evaluation of peripheral adenopathy and splenomegaly, and other conditions in the differential diagnosis are discussed separately. (See  <a class="medical medical_review" href="/d/html/8386.html" rel="external">"Evaluation of peripheral lymphadenopathy in adults"</a> and  <a class="medical medical_review" href="/d/html/7134.html" rel="external">"Splenomegaly and other splenic disorders in adults"</a>.)</p><p class="headingAnchor" id="H15"><span class="h2">Head and neck</span><span class="headingEndMark"> — </span>Enlargement of preauricular nodes or tonsillar asymmetry may suggest the presence of nodal or extranodal involvement of the head and neck, including Waldeyer's ring (tonsils, base of the tongue, nasopharynx) [<a href="#rid32">32</a>]. Involvement of the orbital structures (eg, eyelid, extraocular muscles, lacrimal apparatus, conjunctivae) is rare [<a href="#rid33">33</a>] but may be seen as a feature of marginal zone lymphoma, mantle cell lymphoma, or primary central nervous system (CNS) lymphoma. (See  <a class="medical medical_review" href="/d/html/4733.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of extranodal marginal zone lymphoma of mucosa associated lymphoid tissue (MALT)"</a>.)</p><p class="headingAnchor" id="H16"><span class="h2">Chest and lungs</span><span class="headingEndMark"> — </span>The presence of lymphoma in the thoracic cavity may be suggested by superior vena cava syndrome, pleural or pericardial effusions, or associated clinical findings (eg, dyspnea, cough, hemoptysis, wheeze, stridor, tachypnea, hypotension, swelling of the face or neck, peripheral edema). Mediastinal involvement can be seen either as the sole site of disease (eg, primary mediastinal large B cell lymphoma) or as a manifestation of systemic disease. (See  <a class="medical medical_review" href="/d/html/2832.html" rel="external">"Malignancy-related superior vena cava syndrome"</a> and  <a class="medical medical_review" href="/d/html/4713.html" rel="external">"Primary mediastinal large B cell lymphoma"</a>.)</p><p class="headingAnchor" id="H17"><span class="h2">Abdomen and pelvis</span><span class="headingEndMark"> — </span>Involvement of retroperitoneal, mesenteric, and pelvic nodes is common in most histologic subtypes of NHL  (<a class="graphic graphic_diagnosticimage graphicRef88751" href="/d/graphic/88751.html" rel="external">image 1</a>). Unless it is massive or leads to obstruction, nodal enlargement in these sites usually does not produce symptoms or findings on physical examination.</p><p>While diffuse hepatosplenomegaly  (<a class="graphic graphic_diagnosticimage graphicRef71379" href="/d/graphic/71379.html" rel="external">image 2</a>) is common in the indolent lymphomas, synthetic liver function is usually intact. In contrast, discrete hepatic and splenic masses are more commonly seen in the aggressive or highly aggressive subtypes  (<a class="graphic graphic_diagnosticimage graphicRef59628" href="/d/graphic/59628.html" rel="external">image 3</a>) [<a href="#rid34">34,35</a>]. </p><p>However, not all focal liver lesions in patients with NHL are due to lymphoma. As an example, in one study of 414 consecutive patients with NHL, only 39 percent of the detected focal liver lesions at disease onset were due to NHL; 58 percent were non-malignant [<a href="#rid36">36</a>]. Conversely, 74 percent of the liver lesions detected during follow-up were due to NHL, while 15 percent were due to a malignancy other than NHL (eg, hepatocellular carcinoma, metastatic lesions from a second malignancy).</p><p>Ascites may be present and can be chylous in the setting of lymphatic obstruction if infiltration or compression of lymphatic vessels in the chest (thoracic duct) or abdomen (cisterna chyli or one of its mesenteric tributaries) has occurred. (See  <a class="medical medical_review" href="/d/html/1235.html" rel="external">"Chylous, bloody, and pancreatic ascites"</a>.)</p><p class="headingAnchor" id="H18"><span class="h2">Extranodal sites</span><span class="headingEndMark"> — </span>Less than one-third of patients have primary extranodal lymphoma at presentation. Symptoms due to extranodal disease are usually associated with aggressive NHL and are uncommon in the indolent lymphomas.</p><p>The most common site of primary extranodal disease is the gastrointestinal tract  (<a class="graphic graphic_diagnosticimage graphicRef72998" href="/d/graphic/72998.html" rel="external">image 4</a>) followed by skin; other extranodal sites involved by aggressive NHLs include testis, bone, and CNS; rarely, kidney, prostate, bladder, ovary, orbit, heart, breast, salivary glands, thyroid, and adrenal glands may be involved [<a href="#rid33">33,37-47</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>The skin should be carefully examined and all suspicious areas should be biopsied for the presence of lymphoma. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Testicular NHL, presenting as a mass, constitutes 1 percent of all NHLs and 2 percent of all extranodal lymphomas; it is the most common malignancy involving the testis in men &gt;60 years  (<a class="graphic graphic_diagnosticimage graphicRef50490" href="/d/graphic/50490.html" rel="external">image 5</a>) [<a href="#rid48">48</a>]. (See  <a class="medical medical_review" href="/d/html/2949.html" rel="external">"Anatomy and pathology of testicular tumors", section on 'Testicular lymphoma'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>NHL of bone is usually the manifestation of disseminated disease but can present as a solitary lesion, usually with pain, mass, swelling, or pathologic fracture  (<a class="graphic graphic_diagnosticimage graphicRef66388" href="/d/graphic/66388.html" rel="external">image 6</a>). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Epidural spinal cord compression (ESCC) is a medical emergency that can cause irreversible loss of motor, sensory, and/or autonomic function. NHL is thought to first involve the paraspinal soft tissues and to then invade the cord via the vertebral foramen without first causing bony destruction [<a href="#rid49">49,50</a>]. ESCC can occur as an initial manifestation of NHL or later in the course of disease. (See  <a class="medical medical_review" href="/d/html/2819.html" rel="external">"Clinical features and diagnosis of neoplastic epidural spinal cord compression"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>NHL can involve the CNS, either as the sole area of disease (primary CNS lymphoma) or as secondary spread of systemic disease. Primary CNS lymphoma constitutes only 1 percent of all NHLs. Direct lymphomatous involvement of peripheral nerves (neurolymphomatosis) is a rare event, often occurring in the presence of widespread systemic disease [<a href="#rid51">51</a>]. (See  <a class="medical medical_review" href="/d/html/5180.html" rel="external">"Overview of the clinical features and diagnosis of brain tumors in adults"</a> and  <a class="medical medical_review" href="/d/html/4720.html" rel="external">"Secondary central nervous system lymphoma: Clinical features and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Clinical evidence of renal involvement occurs in 2 to 14 percent of patients with NHL, usually of the aggressive or highly aggressive subtypes, but rarely presents with symptoms of renal failure at diagnosis  (<a class="graphic graphic_diagnosticimage graphicRef81101" href="/d/graphic/81101.html" rel="external">image 7</a>). Ureteral obstruction due to retroperitoneal disease or tubular obstruction due to acute uric acid nephropathy are more likely causes of renal insufficiency at the time of diagnosis. (See  <a class="medical medical_review" href="/d/html/7173.html" rel="external">"Overview of kidney disease in patients with cancer"</a> and  <a class="medical medical_review" href="/d/html/7379.html" rel="external">"Uric acid kidney diseases", section on 'Acute uric acid nephropathy'</a>.)</p><p></p><p class="headingAnchor" id="H807943485"><span class="h1">IMAGING</span><span class="headingEndMark"> — </span>Imaging can identify sites of lymph node or organ involvement by NHL and aid in the selection of a site and/or guide a diagnostic biopsy.</p><p>Ultrasound and computed tomography (CT) are commonly used as a guide for a diagnostic biopsy. Positron emission tomography (PET) alone, or combined with CT, can be useful for identifying suspicious lymph nodes with lymphomas that are fluorodeoxyglucose (FDG)-avid. For these purposes, essentially all types of nodal lymphoma are considered FDG-avid, except chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), lymphoplasmacytic lymphoma/Waldenström macroglobulinemia, mycosis fungoides, and marginal zone lymphoma; however, if transformation of an indolent lymphoma is suspected, PET/CT may be useful for identifying a preferred biopsy site.</p><p>The use of CT and PET/CT imaging for staging NHL is discussed separately. (See  <a class="medical medical_review" href="/d/html/4696.html" rel="external">"Pretreatment evaluation and staging of non-Hodgkin lymphomas", section on 'Choice of imaging modality'</a>.)</p><p class="headingAnchor" id="H19"><span class="h1">LYMPH NODE AND TISSUE BIOPSY</span><span class="headingEndMark"> — </span>A biopsy is required for the diagnosis and classification of NHL. This should be obtained urgently if an aggressive NHL is suspected and, ideally, before treatment with steroids (which may obscure the diagnosis because they are lympholytic). Evaluation by a hematopathologist or a pathologist with expertise in lymphoma improves diagnostic accuracy and may affect clinical management [<a href="#rid52">52</a>].</p><p class="headingAnchor" id="H3238734060"><span class="h2">Type of biopsy</span><span class="headingEndMark"> — </span>Lymph nodes can be evaluated by excisional or incisional biopsy, core needle biopsy, or fine needle aspiration (FNA). It is preferable to obtain adequate biopsy material so that both the diagnosis and classification of a lymphoma can be established with a single procedure. Submission of fresh tissue (ie, unfixed tissue), with or without formalin-fixed tissue, is preferable when possible. The importance of adequate tissue samples for accurate diagnosis and expert pathologic review cannot be overemphasized [<a href="#rid53">53-56</a>].</p><p>In general, an excisional or incisional biopsy of a lymph node or multiple core needle biopsies are required to consistently provide adequate tissue for histologic, immunologic, and molecular biologic assessment. Some clinicians use FNA as an initial evaluation of lymphadenopathy. However, an FNA is neither adequate to exclude a diagnosis of lymphoma (eg, due to limited diagnostic material, sampling issues, loss of fragile cells during processing) nor does it enable definitive classification (because it disrupts the nodal architecture). If an FNA suggests the presence of a lymphoma, it should be followed up with a definitive tissue biopsy [<a href="#rid53">53,57,58</a>]. (See  <a class="medical medical_review" href="/d/html/8386.html" rel="external">"Evaluation of peripheral lymphadenopathy in adults", section on 'Localized lymphadenopathy'</a>.)</p><p>Although a biopsy fixed in formalin may be adequate to establish the diagnosis of a lymphoma, unfixed tissue is needed for flow cytometry and karyotyping, which are often helpful in arriving at a definitive and specific diagnosis.</p><p class="headingAnchor" id="H20"><span class="h2">Lymph node selection</span><span class="headingEndMark"> — </span>When available, a lymph node is generally the preferred tissue for diagnosis of an NHL.</p><p>Selection of a lymph node to biopsy depends on the clinical situation and the location of involved nodes. A lymph node should be considered for biopsy if one or more of the following lymph node characteristics is present:</p><p class="bulletIndent1"><span class="glyph">●</span>Significant enlargement – In general, lymph nodes &gt;2.25 cm<sup>2</sup> (ie, a node with biperpendicular diameters of 1.5 x 1.5 cm) or 2 cm in a single diameter have the best diagnostic yields, whereas lymph nodes &lt;1 cm diameter are unlikely to provide a specific diagnosis [<a href="#rid59">59,60</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Persistence for &gt;4 to 6 weeks.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Progressive increase in size.</p><p></p><p>Enlarged peripheral lymph nodes are generally preferred because they are easily accessed, have a high diagnostic yield, and are associated with lower procedural risk, when compared with most other sites. If possible, we avoid biopsy of inguinal lymph nodes to avoid infectious complications and because they frequently reveal an inflammatory/reactive pattern that may obscure the diagnosis of lymphoma. When palpably enlarged peripheral lymph nodes are not present, ultrasound, computed tomography (CT), or laparoscopy can be used to obtain diagnostic material in a majority of cases [<a href="#rid61">61,62</a>].</p><p class="headingAnchor" id="H1440793069"><span class="h2">Other tissues</span><span class="headingEndMark"> — </span>Biopsy of a lymph node is usually the preferred diagnostic test for most patients with NHL. However, some subtypes of NHL do not present with overt lymphadenopathy, and they may require evaluation of another tissue for diagnosis. Pathologic evaluation of these tissues may also be necessary for the staging of patients with signs or symptoms worrisome for involvement of these sites or for patients with subtypes of NHL that have a high incidence of involvement of these tissues.</p><p class="headingAnchor" id="H3295076784"><span class="h3">Bone marrow</span><span class="headingEndMark"> — </span>Rarely, bone marrow is the only available site to make the diagnosis of NHL. Bone marrow aspirate and biopsy should be evaluated by histologic, immunophenotypic, cytogenetic, and molecular studies by an experienced hematopathologist, as described below. (See <a class="local">'Analysis of biopsy material'</a> below.) </p><p>Use of bone marrow examination for lymphoma staging is discussed separately. (See  <a class="medical medical_review" href="/d/html/4696.html" rel="external">"Pretreatment evaluation and staging of non-Hodgkin lymphomas", section on 'Bone marrow examination'</a>.)</p><p class="headingAnchor" id="H2607835435"><span class="h3">Cerebrospinal fluid</span><span class="headingEndMark"> — </span>Lumbar puncture with analysis of the cerebrospinal fluid (CSF) is indicated for patients suspected of having leptomeningeal metastases (lymphomatous meningitis) or primary central nervous system (CNS) lymphoma and for patients with subtypes of NHL that have a high incidence of CNS involvement (eg, Burkitt lymphoma). </p><p>If there is lymphomatous involvement, the CSF examination usually reveals an elevated protein concentration and a lymphocyte-predominant pleocytosis. Glucose concentration is usually normal but may be low. The presence of malignant lymphoid cells is usually confirmed by flow cytometry, but immunohistochemistry or cytology of cytospin preparations may also demonstrate lymphoma cells [<a href="#rid63">63</a>]. (See  <a class="medical medical_review" href="/d/html/5180.html" rel="external">"Overview of the clinical features and diagnosis of brain tumors in adults"</a> and  <a class="medical medical_review" href="/d/html/4720.html" rel="external">"Secondary central nervous system lymphoma: Clinical features and diagnosis"</a>.)</p><p class="headingAnchor" id="H2665347213"><span class="h3">Pleural/pericardial fluid</span><span class="headingEndMark"> — </span>Pleural effusion and/or pericardial fluid should be evaluated for lymphoma involvement. The most common causes are secondary involvement of the body fluid by a systemic lymphoma (ie, secondary effusion), extranodal variants of various subtypes of lymphoma (eg, extranodal large cell lymphoma), and lymphomas that develop primarily within pleural effusions (ie, primary effusion lymphoma, pyothorax-associated lymphoma). (See  <a class="medical medical_review" href="/d/html/4752.html" rel="external">"Primary effusion lymphoma", section on 'Differential diagnosis'</a>.)</p><p>Common findings include an elevated protein concentration, a lymphocyte-predominant pleocytosis, and a normal or low glucose concentration. Reactive T cells may be more prominent than the neoplastic cells. The presence of malignant lymphoid cells can be confirmed by flow cytometry, immunohistochemistry, or cytology performed on cytospin preparations or cell blocks.</p><p class="headingAnchor" id="H2626727441"><span class="h3">Peritoneal fluid</span><span class="headingEndMark"> — </span>Peritoneal fluid sampling is indicated if ascites is present. Such involvement can develop in the context of a systemic nodal lymphoma or as a primary effusion lymphoma. (See  <a class="medical medical_review" href="/d/html/4752.html" rel="external">"Primary effusion lymphoma"</a>.)</p><p>Common findings include an elevated protein concentration, a lymphocyte-predominant pleocytosis, and a normal or low glucose concentration. Reactive T cells may be more prominent than the neoplastic cells, and the presence of malignant lymphoid cells may be confirmed by flow cytometry, immunohistochemistry, cytology, or molecular analysis.</p><p class="headingAnchor" id="H495152132"><span class="h3">Spleen</span><span class="headingEndMark"> — </span>In some centers, splenic biopsy can be used for diagnosis of a lymphoma [<a href="#rid64">64</a>]. The most common subtypes of lymphoma that are confined to the spleen include splenic marginal zone lymphoma, splenic red pulp lymphoma, and hepatosplenic T cell lymphoma. Pathologic findings in such cases vary depending upon the histologic subtype. (See  <a class="medical medical_review" href="/d/html/4731.html" rel="external">"Splenic marginal zone lymphoma"</a> and  <a class="medical medical_review" href="/d/html/4714.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of hepatosplenic T cell lymphoma"</a>.)</p><p class="headingAnchor" id="H25"><span class="h1">ANALYSIS OF BIOPSY MATERIAL</span><span class="headingEndMark"> — </span>The diagnosis of lymphoma is based on a comprehensive evaluation of histologic, immunophenotypic, cytogenetic, and molecular studies that are interpreted in the context of the clinical scenario. When possible, biopsy specimens should include both fresh tissue and formalin-fixed material and should be evaluated by an experienced hematopathologist [<a href="#rid65">65</a>].</p><p class="headingAnchor" id="H26"><span class="h2">Histology</span><span class="headingEndMark"> — </span>The histologic evaluation of a lymphoma includes assessment of the morphology of the individual tumor cells and the pattern of lymph node involvement, which is best appreciated through examination of an intact lymph node.</p><p>The evaluation of biopsy material should determine if there is effacement or preservation of the normal lymph node architecture. Determining the aspects of a lymph node that are infiltrated by malignant cells (eg, follicular, perifollicular, interfollicular areas) are important for defining the subtype of NHL. Patterns of lymph node involvement may include:</p><p class="bulletIndent1"><span class="glyph">●</span>Nodular/follicular pattern  (<a class="graphic graphic_picture graphicRef69885" href="/d/graphic/69885.html" rel="external">picture 1</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Diffuse pattern  (<a class="graphic graphic_picture graphicRef81795" href="/d/graphic/81795.html" rel="external">picture 2</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Change from a nodular to a diffuse pattern in adjacent nodes  (<a class="graphic graphic_picture graphicRef79473" href="/d/graphic/79473.html" rel="external">picture 3</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Change from a lower to a higher grade of involvement within a single node  (<a class="graphic graphic_picture graphicRef53282" href="/d/graphic/53282.html" rel="external">picture 4</a>)</p><p></p><p class="headingAnchor" id="H27"><span class="h2">Immunophenotype</span><span class="headingEndMark"> — </span>The immunophenotype of lymphoma cells can be determined by flow cytometry performed on fresh, unfixed single cell suspensions or by immunohistochemistry on tissue sections. Improvements in antigen retrieval have greatly enhanced immunohistochemical detection of markers in formalin-fixed, paraffin-embedded (FFPE) tissue, obviating the need for fresh frozen tissue for immunophenotyping by immunohistochemistry.</p><p>Immunophenotyping is crucial for the diagnosis and subclassification of most forms of NHL, which are generally divided according to whether they are of B, T, or natural killer (NK) cell derivation. Expression of cell surface lymphoid differentiation antigens is used to distinguish between B and T cells at various developmental stages  (<a class="graphic graphic_table graphicRef78061" href="/d/graphic/78061.html" rel="external">table 4</a>). (See  <a class="medical medical_review" href="/d/html/13933.html" rel="external">"Normal B and T lymphocyte development"</a>.)</p><p>Flow cytometry is complementary to immunohistochemistry, as it enables simultaneous detection of multiple markers (antigens), has a rapid turnaround time (hours), provides reproducible quantitation (ie, high versus lower levels of antigen expression), and more reliably detects certain markers (eg, surface immunoglobulin light chains) than immunohistochemistry. Flow cytometry is especially useful for diagnostic testing of fine needle aspiration (FNA) specimens.</p><p>Nearly all diagnostically relevant lymphoid markers can be effectively evaluated in FFPE tissue sections. Immunoglobulin light chains can be detected with substantially higher sensitivity in fresh frozen tissue sections but, in practice, assessment of clonality is usually evaluated by flow cytometry or molecular techniques. (See <a class="local">'Molecular analysis'</a> below.)</p><p class="headingAnchor" id="H28"><span class="h2">Cytogenetic studies</span><span class="headingEndMark"> — </span>Cytogenetic studies are important adjuncts for the diagnosis of NHL, as certain chromosomal abnormalities are characteristic for particular types of lymphoma.</p><p>Cytogenetic abnormalities can be detected by conventional karyotype or by fluorescence in situ hybridization (FISH). The preferred technique depends on the clinical situation, available tissue, and suspected diagnosis. Fresh tissue is generally used to perform a conventional karyotype and evaluate chromosomal translocations, while fresh or fixed tissue can be used for FISH. Technical aspects of these techniques are discussed separately. (See  <a class="medical medical_review" href="/d/html/4482.html" rel="external">"General aspects of cytogenetic analysis in hematologic malignancies"</a> and  <a class="medical medical_review" href="/d/html/2893.html" rel="external">"Tools for genetics and genomics: Cytogenetics and molecular genetics", section on 'Detecting cytogenetic abnormalities'</a>.)</p><p class="headingAnchor" id="H843435909"><span class="h2">Molecular analysis</span><span class="headingEndMark"> — </span>Molecular analysis of a biopsy specimen may involve testing for mutations, gene rearrangements, gain or loss of certain genes, and/or epigenetic alterations. Various techniques may be used, including polymerase chain reaction (PCR), DNA sequencing, gene expression studies, and genomic analysis. Discussion of these techniques is presented separately. (See  <a class="medical medical_review" href="/d/html/2896.html" rel="external">"Polymerase chain reaction (PCR)"</a> and  <a class="medical medical_review" href="/d/html/2893.html" rel="external">"Tools for genetics and genomics: Cytogenetics and molecular genetics"</a>.)f </p><p>Examples of use of molecular studies to aid the evaluation of lymphomas include:</p><p class="bulletIndent1"><span class="glyph">●</span>Immunoglobulin (Ig) gene rearrangement studies using PCR can determine clonality of B-lymphocytes, since every normal B-lymphocyte carries one or two rearranged Ig heavy chain genes (<em>IgH</em>) with a unique DNA sequence [<a href="#rid66">66</a>]. PCR with consensus <em>IgH</em> primers followed by sizing of products by capillary electrophoresis detects clonal rearrangements in about 85 percent of B cell lymphomas [<a href="#rid67">67</a>]. PCR testing is rapid, does not require radioactivity, and can be performed reliably on DNA retrieved from FFPE tissues; for these reasons, it has supplanted Southern blot analysis. (See  <a class="medical medical_review" href="/d/html/3977.html" rel="external">"Immunoglobulin genetics"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Similarly, T cell receptor (<em>TCR</em>) gene rearrangement studies using PCR can determine if T-lymphocytes are clonal or nonclonal [<a href="#rid66">66</a>]. The TCR is composed of several subunits, including heterodimers composed of the alpha/beta and gamma/delta chains in association with the CD3 complex. PCR is conducted with consensus primers designed to amplify rearranged <em>TCR</em> gamma genes. When coupled to precise sizing of products by capillary electrophoresis, this test detects clonal rearrangements in about 90 percent of T cell lymphomas [<a href="#rid67">67</a>]. As with Ig rearrangements, PCR has replaced Southern blot analysis. (See  <a class="medical medical_review" href="/d/html/3950.html" rel="external">"T-B-NK+ SCID: Pathogenesis, clinical manifestations, and diagnosis", section on 'T cell receptor generation'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Gene expression profiling (GEP) can be used to stratify diffuse large B cell lymphoma into different risk groups. While potentially helpful, to date, GEP has mainly been restricted to the clinical research arena because of the requirement for fresh tissue and technical complexity. Newer technologies can reliably generate GEPs using RNA retrieved from FFPE tissues [<a href="#rid68">68</a>], but they have yet to become a standard part of lymphoma characterization and classification. (See  <a class="medical medical_review" href="/d/html/83821.html" rel="external">"Prognosis of diffuse large B cell lymphoma", section on 'Gene expression profiling'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>DNA sequencing is being evaluated for diagnosis and stratification of NHL but has not yet been validated for clinical practice. Many centers use DNA sequencing to identify somatic mutations that are characteristic of certain lymphomas (eg, <em>MYD88</em> mutations in lymphoplasmacytic lymphoma), and routine use of DNA sequencing as part of the work-up of NHL is likely to continue to increase. (See  <a class="medical medical_review" href="/d/html/4768.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of lymphoplasmacytic lymphoma", section on 'MYD88 mutations'</a>.)</p><p></p><p>These and other studies can be important adjunct tests, particularly when samples are obtained by FNA, where limited diagnostic material is available for conventional histologic evaluation [<a href="#rid69">69</a>].</p><p class="headingAnchor" id="H1019732220"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/117911.html" rel="external">"Society guideline links: Lymphoma diagnosis and staging"</a>.)</p><p class="headingAnchor" id="H985998"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient education" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/15492.html" rel="external">"Patient education: Lymphoma (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H36"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Non-Hodgkin lymphomas (NHLs)</strong> – NHLs are malignancies of B-cell, T-cell, or T/NK (natural killer) cell lineages. NHLs range from indolent disorders to highly aggressive malignancies and they can involve lymph nodes, other lymphoid tissues, extranodal sites, and/or blood or bone marrow. NHLs differ from Hodgkin lymphomas based on pathophysiology, histology, natural history, and treatment. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation</strong> – The clinical presentation varies with the type of NHL. Lymphadenopathy and/or hepatosplenomegaly are the most common presentations and some patients have constitutional symptoms (ie, fever, weight loss, night sweats). Less common presentations are symptoms related to extranodal disease, an oncologic emergency, paraneoplastic syndrome, or isolated laboratory abnormalities. (See <a class="local">'Clinical presentation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Emergencies</strong> – Tumor lysis syndrome, spinal cord compression, compression of a major airway, or involvement of the central nervous system (CNS) is seen with some NHLs and may require immediate management, even while the diagnosis of NHL is being established. (See <a class="local">'Oncologic emergencies'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial evaluation</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Clinical</strong> – History and physical examination should assess lymphadenopathy (which is generally firm and painless)  (<a class="graphic graphic_figure graphicRef63663" href="/d/graphic/63663.html" rel="external">figure 2</a>), organomegaly, constitutional symptoms, extranodal involvement, and medical conditions that may affect management. (See <a class="local">'History'</a> above and <a class="local">'Physical examination'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Laboratory</strong> – Initial laboratory studies should include: </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Hematology</strong> – Complete blood count (CBC) with differential count, coagulation studies</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Serum chemistries</strong> – Electrolytes, renal function tests, liver function tests, lactate dehydrogenase (LDH), and uric acid</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnostic evaluation</strong> – For patients suspected to have an NHL based on clinical or laboratory findings, analysis of an involved lymph node or other involved tissue is required. Whenever possible, the biopsy specimen should be obtained before administration of a glucocorticoid, because steroids are lymphocytolytic and may interfere with analysis. (See <a class="local">'Lymph node and tissue biopsy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Preferred biopsy specimen </strong>– An excisional lymph node biopsy is preferred; if this is not possible, an incisional biopsy or multiple core biopsies are acceptable. Importantly, fine needle aspiration is generally not an acceptable substitute, because it provides only limited tissue and does not enable evaluation of the lymph node architecture, which is needed to classify the lymphoma. (See <a class="local">'Lymph node and tissue biopsy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Alternative tissue specimens</strong> – If no lymph node is accessible, biopsy of a site of extranodal involvement, liver, or bone marrow is acceptable. (See <a class="local">'Other tissues'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Analysis </strong>– Diagnosis and classification of a lymphoma requires (see <a class="local">'Analysis of biopsy material'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Histology</strong> – Microscopic appearance of the malignant cells and the pattern of involvement of the lymph node  (<a class="graphic graphic_picture graphicRef69885" href="/d/graphic/69885.html" rel="external">picture 1</a>) or extranodal site (See <a class="local">'Histology'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Immunophenotype</strong> – Immunophenotype of the malignant cells by flow cytometry or immunohistochemistry (See <a class="local">'Immunophenotype'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Cytogenetics </strong>– Conventional karyotype or fluorescence in situ hybridization (FISH); the preferred technique depends on the clinical situation, available tissue, and suspected diagnosis (See <a class="local">'Cytogenetic studies'</a> above.) </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Molecular analysis </strong>– Analysis for mutations, gene rearrangements, and gain or loss of certain genes, by polymerase chain reaction (PCR), DNA sequencing, or other techniques (See <a class="local">'Molecular analysis'</a> above.) </p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 1998; 16:2780.</a></li><li><a class="nounderline abstract_t">Frumkin H. Agent Orange and cancer: an overview for clinicians. CA Cancer J Clin 2003; 53:245.</a></li><li><a class="nounderline abstract_t">Engels EA, Cerhan JR, Linet MS, et al. Immune-related conditions and immune-modulating medications as risk factors for non-Hodgkin's lymphoma: a case-control study. Am J Epidemiol 2005; 162:1153.</a></li><li><a class="nounderline abstract_t">Talamini R, Montella M, Crovatto M, et al. Non-Hodgkin's lymphoma and hepatitis C virus: a case-control study from northern and southern Italy. Int J Cancer 2004; 110:380.</a></li><li><a class="nounderline abstract_t">Negri E, Little D, Boiocchi M, et al. B-cell non-Hodgkin's lymphoma and hepatitis C virus infection: a systematic review. Int J Cancer 2004; 111:1.</a></li><li><a class="nounderline abstract_t">Takkouche B, Etminan M, Montes-Martínez A. Personal use of hair dyes and risk of cancer: a meta-analysis. JAMA 2005; 293:2516.</a></li><li><a class="nounderline abstract_t">Altieri A, Bermejo JL, Hemminki K. Familial risk for non-Hodgkin lymphoma and other lymphoproliferative malignancies by histopathologic subtype: the Swedish Family-Cancer Database. Blood 2005; 106:668.</a></li><li><a class="nounderline abstract_t">Kandiel A, Fraser AG, Korelitz BI, et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 2005; 54:1121.</a></li><li><a class="nounderline abstract_t">Brennan P, Scélo G, Hemminki K, et al. Second primary cancers among 109 000 cases of non-Hodgkin's lymphoma. Br J Cancer 2005; 93:159.</a></li><li><a class="nounderline abstract_t">Smedby KE, Hjalgrim H, Askling J, et al. Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype. J Natl Cancer Inst 2006; 98:51.</a></li><li><a class="nounderline abstract_t">Saadoun D, Sellam J, Ghillani-Dalbin P, et al. Increased risks of lymphoma and death among patients with non-hepatitis C virus-related mixed cryoglobulinemia. Arch Intern Med 2006; 166:2101.</a></li><li><a class="nounderline abstract_t">Chiu BC, Dave BJ, Blair A, et al. Agricultural pesticide use and risk of t(14;18)-defined subtypes of non-Hodgkin lymphoma. Blood 2006; 108:1363.</a></li><li><a class="nounderline abstract_t">Rafnsson V. Risk of non-Hodgkin's lymphoma and exposure to hexachlorocyclohexane, a nested case-control study. Eur J Cancer 2006; 42:2781.</a></li><li><a class="nounderline abstract_t">Ramos-Casals M, la Civita L, de Vita S, et al. Characterization of B cell lymphoma in patients with Sjögren's syndrome and hepatitis C virus infection. Arthritis Rheum 2007; 57:161.</a></li><li><a class="nounderline abstract_t">Chang ET, Smedby KE, Hjalgrim H, et al. Family history of hematopoietic malignancy and risk of lymphoma. J Natl Cancer Inst 2005; 97:1466.</a></li><li><a class="nounderline abstract_t">Wang SS, Slager SL, Brennan P, et al. Family history of hematopoietic malignancies and risk of non-Hodgkin lymphoma (NHL): a pooled analysis of 10 211 cases and 11 905 controls from the International Lymphoma Epidemiology Consortium (InterLymph). Blood 2007; 109:3479.</a></li><li><a class="nounderline abstract_t">Lu Y, Sullivan-Halley J, Cozen W, et al. Family history of haematopoietic malignancies and non-Hodgkin's lymphoma risk in the California Teachers Study. Br J Cancer 2009; 100:524.</a></li><li><a class="nounderline abstract_t">Goldin LR, Björkholm M, Kristinsson SY, et al. Highly increased familial risks for specific lymphoma subtypes. Br J Haematol 2009; 146:91.</a></li><li><a class="nounderline abstract_t">Herro E, Dicaudo DJ, Davis MD, et al. Review of contemporaneous mycosis fungoides and B-cell malignancy at Mayo Clinic. J Am Acad Dermatol 2009; 61:271.</a></li><li><a class="nounderline abstract_t">Cerhan JR, Slager SL. Familial predisposition and genetic risk factors for lymphoma. Blood 2015; 126:2265.</a></li><li><a class="nounderline abstract_t">Sud A, Chattopadhyay S, Thomsen H, et al. Analysis of 153 115 patients with hematological malignancies refines the spectrum of familial risk. Blood 2019; 134:960.</a></li><li><a class="nounderline abstract_t">Clarke CA, Morton LM, Lynch C, et al. Risk of lymphoma subtypes after solid organ transplantation in the United States. Br J Cancer 2013; 109:280.</a></li><li><a class="nounderline abstract_t">Ulcickas Yood M, Quesenberry CP Jr, Guo D, et al. Incidence of non-Hodgkin's lymphoma among individuals with chronic hepatitis B virus infection. Hepatology 2007; 46:107.</a></li><li><a class="nounderline abstract_t">Wang F, Xu RH, Han B, et al. High incidence of hepatitis B virus infection in B-cell subtype non-Hodgkin lymphoma compared with other cancers. Cancer 2007; 109:1360.</a></li><li><a class="nounderline abstract_t">Viswanatha DS, Dogan A. Hepatitis C virus and lymphoma. J Clin Pathol 2007; 60:1378.</a></li><li><a class="nounderline abstract_t">Clemens MW, Medeiros LJ, Butler CE, et al. Complete Surgical Excision Is Essential for the Management of Patients With Breast Implant-Associated Anaplastic Large-Cell Lymphoma. J Clin Oncol 2016; 34:160.</a></li><li><a class="nounderline abstract_t">Nakatsuka S, Yao M, Hoshida Y, et al. Pyothorax-associated lymphoma: a review of 106 cases. J Clin Oncol 2002; 20:4255.</a></li><li><a class="nounderline abstract_t">Ekström Smedby K, Vajdic CM, Falster M, et al. Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. Blood 2008; 111:4029.</a></li><li><a class="nounderline abstract_t">Goldin LR, Landgren O. Autoimmunity and lymphomagenesis. Int J Cancer 2009; 124:1497.</a></li><li><a class="nounderline abstract_t">Anderson LA, Gadalla S, Morton LM, et al. Population-based study of autoimmune conditions and the risk of specific lymphoid malignancies. Int J Cancer 2009; 125:398.</a></li><li><a class="nounderline abstract_t">Fallah M, Liu X, Ji J, et al. Autoimmune diseases associated with non-Hodgkin lymphoma: a nationwide cohort study. Ann Oncol 2014; 25:2025.</a></li><li><a class="nounderline abstract_t">Urquhart A, Berg R. Hodgkin's and non-Hodgkin's lymphoma of the head and neck. Laryngoscope 2001; 111:1565.</a></li><li><a class="nounderline abstract_t">Bhatia S, Paulino AC, Buatti JM, et al. Curative radiotherapy for primary orbital lymphoma. Int J Radiat Oncol Biol Phys 2002; 54:818.</a></li><li><a class="nounderline abstract_t">Goffinet DR, Castellino RA, Kim H, et al. Staging laparotomies in unselected previously untreated patients with non-Hodgkin's lymphomas. Cancer 1973; 32:672.</a></li><li><a class="nounderline abstract_t">Risdall R, Hoppe RT, Warnke R. Non-Hodgkin's lymphoma: a study of the evolution of the disease based upon 92 autopsied cases. Cancer 1979; 44:529.</a></li><li><a class="nounderline abstract_t">Civardi G, Vallisa D, Bertè R, et al. Focal liver lesions in non-Hodgkin's lymphoma: investigation of their prevalence, clinical significance and the role of Hepatitis C virus infection. Eur J Cancer 2002; 38:2382.</a></li><li><a class="nounderline abstract_t">Aozasa K, Inoue A, Tajima K, et al. Malignant lymphomas of the thyroid gland. Analysis of 79 patients with emphasis on histologic prognostic factors. Cancer 1986; 58:100.</a></li><li><a class="nounderline abstract_t">Gill PS, Chandraratna PA, Meyer PR, Levine AM. Malignant lymphoma: cardiac involvement at initial presentation. J Clin Oncol 1987; 5:216.</a></li><li><a class="nounderline abstract_t">Gleeson MJ, Bennett MH, Cawson RA. Lymphomas of salivary glands. Cancer 1986; 58:699.</a></li><li><a class="nounderline abstract_t">Harris GJ, Tio FO, Von Hoff DD. Primary adrenal lymphoma. Cancer 1989; 63:799.</a></li><li><a class="nounderline abstract_t">Bostwick DG, Mann RB. Malignant lymphomas involving the prostate. A study of 13 cases. Cancer 1985; 56:2932.</a></li><li><a class="nounderline abstract_t">Doll DC, Weiss RB. Malignant lymphoma of the testis. Am J Med 1986; 81:515.</a></li><li><a class="nounderline abstract_t">Paladugu RR, Bearman RM, Rappaport H. Malignant lymphoma with primary manifestation in the gonad: a clinicopathologic study of 38 patients. Cancer 1980; 45:561.</a></li><li><a class="nounderline abstract_t">Woolley PV 3rd, Osborne CK, Levi JA, et al. Extranodal presentation of non-Hodgkin's lymphomas in the testis. Cancer 1976; 38:1026.</a></li><li><a class="nounderline abstract_t">Wong WW, Schild SE, Halyard MY, Schomberg PJ. Primary non-Hodgkin lymphoma of the breast: The Mayo Clinic Experience. J Surg Oncol 2002; 80:19.</a></li><li><a class="nounderline abstract_t">Feinstein AJ, Ciarleglio MM, Cong X, et al. Parotid gland lymphoma: prognostic analysis of 2140 patients. Laryngoscope 2013; 123:1199.</a></li><li><a class="nounderline abstract_t">Ahmad AK, Hui P, Litkouhi B, et al. Institutional review of primary non-hodgkin lymphoma of the female genital tract: a 33-year experience. Int J Gynecol Cancer 2014; 24:1250.</a></li><li><a class="nounderline abstract_t">Seymour JF, Solomon B, Wolf MM, et al. Primary large-cell non-Hodgkin's lymphoma of the testis: a retrospective analysis of patterns of failure and prognostic factors. Clin Lymphoma 2001; 2:109.</a></li><li class="breakAll">Giglio P, Gilbert MR. Neurological complications of non-Hodgkin's lymphoma. In: Lymphoma of the Nervous System, Batchelor TT (Ed), Butterworth Heinemann, Amsterdam 2004. p.107.</li><li><a class="nounderline abstract_t">Perry JR, Deodhare SS, Bilbao JM, et al. The significance of spinal cord compression as the initial manifestation of lymphoma. Neurosurgery 1993; 32:157.</a></li><li><a class="nounderline abstract_t">Ghobrial IM, Buadi F, Spinner RJ, et al. High-dose intravenous methotrexate followed by autologous stem cell transplantation as a potentially effective therapy for neurolymphomatosis. Cancer 2004; 100:2403.</a></li><li><a class="nounderline abstract_t">Laurent C, Baron M, Amara N, et al. Impact of Expert Pathologic Review of Lymphoma Diagnosis: Study of Patients From the French Lymphopath Network. J Clin Oncol 2017; 35:2008.</a></li><li><a class="nounderline abstract_t">Hehn ST, Grogan TM, Miller TP. Utility of fine-needle aspiration as a diagnostic technique in lymphoma. J Clin Oncol 2004; 22:3046.</a></li><li><a class="nounderline abstract_t">Siebert JD, Harvey LA, Fishkin PA, et al. Comparison of lymphoid neoplasm classification. A blinded study between a community and an academic setting. Am J Clin Pathol 2001; 115:650.</a></li><li><a class="nounderline abstract_t">Lester JF, Dojcinov SD, Attanoos RL, et al. The clinical impact of expert pathological review on lymphoma management: a regional experience. Br J Haematol 2003; 123:463.</a></li><li><a class="nounderline abstract_t">Proctor IE, McNamara C, Rodriguez-Justo M, et al. Importance of expert central review in the diagnosis of lymphoid malignancies in a regional cancer network. J Clin Oncol 2011; 29:1431.</a></li><li><a class="nounderline abstract_t">Florentine BD, Staymates B, Rabadi M, et al. The reliability of fine-needle aspiration biopsy as the initial diagnostic procedure for palpable masses: a 4-year experience of 730 patients from a community hospital-based outpatient aspiration biopsy clinic. Cancer 2006; 107:406.</a></li><li><a class="nounderline abstract_t">Hunter S, Samir A, Eisner B, et al. Diagnosis of renal lymphoma by percutaneous image guided biopsy: experience with 11 cases. J Urol 2006; 176:1952.</a></li><li><a class="nounderline abstract_t">Pangalis GA, Vassilakopoulos TP, Boussiotis VA, Fessas P. Clinical approach to lymphadenopathy. Semin Oncol 1993; 20:570.</a></li><li class="breakAll">Benign and Malignant Lymphadenopathies: Clinical and Laboratory Diagnosis, Pangalis G, Polliack A (Eds), Harwood Academic Publishers, Chur, Switzerland 1993. p.31.</li><li><a class="nounderline abstract_t">Lachar WA, Shahab I, Saad AJ. Accuracy and cost-effectiveness of core needle biopsy in the evaluation of suspected lymphoma: a study of 101 cases. Arch Pathol Lab Med 2007; 131:1033.</a></li><li><a class="nounderline abstract_t">Asoglu O, Porter L, Donohue JH, Cha SS. Laparoscopy for the definitive diagnosis of intra-abdominal lymphoma. Mayo Clin Proc 2005; 80:625.</a></li><li><a class="nounderline abstract_t">Wilson WH, Bromberg JE, Stetler-Stevenson M, et al. Detection and outcome of occult leptomeningeal disease in diffuse large B-cell lymphoma and Burkitt lymphoma. Haematologica 2014; 99:1228.</a></li><li><a class="nounderline abstract_t">Hanlon K, Wilson MR, Kay D, et al. Safety and diagnostic yield of splenic core biopsy; a methodical approach using combined Haematology/Radiology assessment in a tertiary referral centre. Br J Haematol 2019; 186:371.</a></li><li><a class="nounderline abstract_t">Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016; 127:2375.</a></li><li><a class="nounderline abstract_t">Langerak AW, Groenen PJ, Brüggemann M, et al. EuroClonality/BIOMED-2 guidelines for interpretation and reporting of Ig/TCR clonality testing in suspected lymphoproliferations. Leukemia 2012; 26:2159.</a></li><li><a class="nounderline abstract_t">van Krieken JH, Langerak AW, Macintyre EA, et al. Improved reliability of lymphoma diagnostics via PCR-based clonality testing: report of the BIOMED-2 Concerted Action BHM4-CT98-3936. Leukemia 2007; 21:201.</a></li><li><a class="nounderline abstract_t">Scott DW, Wright GW, Williams PM, et al. Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. Blood 2014; 123:1214.</a></li><li><a class="nounderline abstract_t">Zeppa P, Marino G, Troncone G, et al. Fine-needle cytology and flow cytometry immunophenotyping and subclassification of non-Hodgkin lymphoma: a critical review of 307 cases with technical suggestions. Cancer 2004; 102:55.</a></li></ol></div><div id="topicVersionRevision">Topic 4695 Version 50.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9704731" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12924777" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Agent Orange and cancer: an overview for clinicians.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16251389" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Immune-related conditions and immune-modulating medications as risk factors for non-Hodgkin's lymphoma: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15095303" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Non-Hodgkin's lymphoma and hepatitis C virus: a case-control study from northern and southern Italy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15185336" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : B-cell non-Hodgkin's lymphoma and hepatitis C virus infection: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15914752" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Personal use of hair dyes and risk of cancer: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15811955" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Familial risk for non-Hodgkin lymphoma and other lymphoproliferative malignancies by histopathologic subtype: the Swedish Family-Cancer Database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16009685" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15970927" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Second primary cancers among 109 000 cases of non-Hodgkin's lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16391371" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17060540" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Increased risks of lymphoma and death among patients with non-hepatitis C virus-related mixed cryoglobulinemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16621961" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Agricultural pesticide use and risk of t(14;18)-defined subtypes of non-Hodgkin lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16934973" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Risk of non-Hodgkin's lymphoma and exposure to hexachlorocyclohexane, a nested case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17266090" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Characterization of B cell lymphoma in patients with Sjögren's syndrome and hepatitis C virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16204696" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Family history of hematopoietic malignancy and risk of lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17185468" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Family history of hematopoietic malignancies and risk of non-Hodgkin lymphoma (NHL): a pooled analysis of 10 211 cases and 11 905 controls from the International Lymphoma Epidemiology Consortium (InterLymph).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19156148" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Family history of haematopoietic malignancies and non-Hodgkin's lymphoma risk in the California Teachers Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19438470" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Highly increased familial risks for specific lymphoma subtypes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19481294" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Review of contemporaneous mycosis fungoides and B-cell malignancy at Mayo Clinic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26405224" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Familial predisposition and genetic risk factors for lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31395603" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Analysis of 153 115 patients with hematological malignancies refines the spectrum of familial risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23756857" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Risk of lymphoma subtypes after solid organ transplantation in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17526021" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Incidence of non-Hodgkin's lymphoma among individuals with chronic hepatitis B virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17326056" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : High incidence of hepatitis B virus infection in B-cell subtype non-Hodgkin lymphoma compared with other cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18042694" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Hepatitis C virus and lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26628470" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Complete Surgical Excision Is Essential for the Management of Patients With Breast Implant-Associated Anaplastic Large-Cell Lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12377970" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Pyothorax-associated lymphoma: a review of 106 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18263783" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19089924" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Autoimmunity and lymphomagenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19365835" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Population-based study of autoimmune conditions and the risk of specific lymphoid malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25081899" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Autoimmune diseases associated with non-Hodgkin lymphoma: a nationwide cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11568605" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Hodgkin's and non-Hodgkin's lymphoma of the head and neck.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12377334" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Curative radiotherapy for primary orbital lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4726967" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Staging laparotomies in unselected previously untreated patients with non-Hodgkin's lymphomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/383257" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Non-Hodgkin's lymphoma: a study of the evolution of the disease based upon 92 autopsied cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12460782" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Focal liver lesions in non-Hodgkin's lymphoma: investigation of their prevalence, clinical significance and the role of Hepatitis C virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3708539" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Malignant lymphomas of the thyroid gland. Analysis of 79 patients with emphasis on histologic prognostic factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3543244" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Malignant lymphoma: cardiac involvement at initial presentation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3731025" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Lymphomas of salivary glands.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2644013" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Primary adrenal lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3840406" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Malignant lymphomas involving the prostate. A study of 13 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3529957" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Malignant lymphoma of the testis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6986200" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Malignant lymphoma with primary manifestation in the gonad: a clinicopathologic study of 38 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/788888" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Extranodal presentation of non-Hodgkin's lymphomas in the testis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11967901" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Primary non-Hodgkin lymphoma of the breast: The Mayo Clinic Experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23576299" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Parotid gland lymphoma: prognostic analysis of 2140 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25010039" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Institutional review of primary non-hodgkin lymphoma of the female genital tract: a 33-year experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11707851" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Primary large-cell non-Hodgkin's lymphoma of the testis: a retrospective analysis of patterns of failure and prognostic factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11707851" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Primary large-cell non-Hodgkin's lymphoma of the testis: a retrospective analysis of patterns of failure and prognostic factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8437651" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : The significance of spinal cord compression as the initial manifestation of lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15160344" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : High-dose intravenous methotrexate followed by autologous stem cell transplantation as a potentially effective therapy for neurolymphomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28459613" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Impact of Expert Pathologic Review of Lymphoma Diagnosis: Study of Patients From the French Lymphopath Network.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15284254" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Utility of fine-needle aspiration as a diagnostic technique in lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11345827" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Comparison of lymphoid neoplasm classification. A blinded study between a community and an academic setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14617006" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : The clinical impact of expert pathological review on lymphoma management: a regional experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21343555" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Importance of expert central review in the diagnosis of lymphoid malignancies in a regional cancer network.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16773630" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : The reliability of fine-needle aspiration biopsy as the initial diagnostic procedure for palpable masses: a 4-year experience of 730 patients from a community hospital-based outpatient aspiration biopsy clinic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17070216" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Diagnosis of renal lymphoma by percutaneous image guided biopsy: experience with 11 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8296196" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Clinical approach to lymphadenopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8296196" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Clinical approach to lymphadenopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17616988" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Accuracy and cost-effectiveness of core needle biopsy in the evaluation of suspected lymphoma: a study of 101 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15887430" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Laparoscopy for the definitive diagnosis of intra-abdominal lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24727817" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Detection and outcome of occult leptomeningeal disease in diffuse large B-cell lymphoma and Burkitt lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30873597" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Safety and diagnostic yield of splenic core biopsy; a methodical approach using combined Haematology/Radiology assessment in a tertiary referral centre.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26980727" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : The 2016 revision of the World Health Organization classification of lymphoid neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22918122" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : EuroClonality/BIOMED-2 guidelines for interpretation and reporting of Ig/TCR clonality testing in suspected lymphoproliferations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17170732" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Improved reliability of lymphoma diagnostics via PCR-based clonality testing: report of the BIOMED-2 Concerted Action BHM4-CT98-3936.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24398326" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14968418" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Fine-needle cytology and flow cytometry immunophenotyping and subclassification of non-Hodgkin lymphoma: a critical review of 307 cases with technical suggestions.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
